Genscript Biotech Corporation

(*Incorporated in the Cayman Islands with limited liability*)

(Stock code: 1548)

PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND THE ADOPTION OF THE AMENDED MEMORANDUM AND ARTICLES OF ASSOCIATION

This announcement is made by Genscript Biotech Corporation (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") in relation to the proposed amendments to the existing fourth amended and restated memorandum of association and the fourth amended and restated articles of association of the Company (the "**Existing Memorandum and Articles**").

The board (the "**Board**") of directors (the "**Directors**") of the Company proposes to amend the Existing Memorandum and Articles to, amongst others, (i) update and bring the Existing Memorandum and Articles in line with the relevant amendments made to the Listing Rules in respect of the hybrid general meetings and the electronic voting, treasury shares and the uncertificated securities market regime, and (ii) better align the amendments of the Existing Memorandum and Articles for housekeeping purposes with the provisions of the Listing Rules and the applicable laws of the Cayman Islands (collectively, the "**Proposed Amendments**"). For the purposes of the Proposed Amendments, the Board proposed to adopt the fifth amended and restated memorandum of association and the fifth amended and restated articles of association (the "**Amended Memorandum and Articles**") which consolidates the Proposed Amendments in substitution for, and to the exclusion of the Existing Memorandum and Articles in their entirety.

The Proposed Amendments and the proposed adoption of the Amended Memorandum and Articles shall be subject to the approval of the shareholders of the Company (the "**Shareholders**") by way of a special resolution at the forthcoming annual general meeting (the "**AGM**") of the Company, and will become effective upon the approval by the Shareholders at the AGM. A circular containing, among other things, further details concerning the Proposed Amendments and the proposed adoption of the Amended Memorandum and Articles, together with the notice of the AGM and the proxy form, will be despatched to the Shareholders in due course.

By order of the Board
Genscript Biotech Corporation
Robin Meng
Chairman and Executive Director

Hong Kong, 10 April 2026

*As at the date of this announcement, the executive Directors are Mr. Jiange Meng ("**Mr. Robin Meng**"), Dr. Fangliang Zhang ("**Dr. Frank Zhang**"), Dr. Li Zhu and Ms. Ye Wang ("**Ms. Sally Wang**"); and the independent non-executive Directors are Dr. Alphonse Galdes, Mr. Yiu Leung Andy Cheung ("**Mr. Andy Cheung**"), Mr. Jiuan Pan ("**Mr. Ethan Pan**"), Dr. John Quelch, Dr. Ross Grossman and Dr. Chenyang Shi ("**Dr. Victor Shi**").*